Schering-Plough Articles
S-P responds to FDA's questions on Saphris NDA
2 March 2009
Organon drug linked with breast cancer
23 February 2009
Sweden's TLV rejects 1st-line use of Pfizer's Lipitor, cites "20 times" cost differential
23 February 2009
Stock Commentary - New York week to Feb 9, 2009
16 February 2009
Ligand gets $1m milestone from S-P
16 February 2009
Mistubishi Tanabe down 15% on R&D costs
16 February 2009
Schering-Plough invest $60M in R&D units
16 February 2009
S-P completes patient enrollment in Ph III boceprevir study
9 February 2009
Stock Commentary - New York week to Feb 2, 2009
9 February 2009
Chikungunya vacc from public-private partnership
9 February 2009
Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders
9 February 2009
New MM drug would do better in USA
26 January 2009
GeoPharma settles Clarinex litigation with S-P et al
26 January 2009
Highlights of first PDCO meeting of 2009
26 January 2009
FDA setback for S-P and Santarus' Zegerid
19 January 2009
FDA requests more existing data on S-P's Saphris before approval
19 January 2009
Pharma/biotech mergers and acquisitions in 2008
12 January 2009
FDA 2008 NCE appros exceed expectations
12 January 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
S-P enters agreement with Huya seeking to license drugs from China
22 December 2008
Lupin settles with S-P over desloratadine
22 December 2008
S-P's Pegintron/Rebetol approved in children
22 December 2008
New US DTC guidelines from PhRMA dismissed by leading Democrats
22 December 2008
FDA divided on safety of Serevent and Foradil ahead of panel meeting
15 December 2008
Stock Commentary - New York week to Dec 1, 2008
8 December 2008
UPDATE: PDCO has good news for Lux Bio and others
8 December 2008
S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years
8 December 2008
Preladenant reduces off-time in Ph II PD trial
8 December 2008
"Unprecedented" 75% SVR24 for boceprevir
1 December 2008
S-P's Saphris effective in schizophrenia relapse
1 December 2008
IFPMA re-elects Fred Hassan as president
24 November 2008
IFPMA report on dev world disease R&D
24 November 2008
IFPMA members gave 11% of health aid
24 November 2008
S-P UK launches Bridion on local market
17 November 2008
Negative press has compromised Vytorin as first-line therapy; DR
17 November 2008
S-P's boceprevir doubles SVR24 in Ph II study
10 November 2008
Stock Commentary - New York week to Nov 3, 2008
10 November 2008
Pegasys/Copegus effective in non-responders
10 November 2008
Schering-Plough to appeal Medicaid case
10 November 2008
S-P's sugammadex produces rapid recovery
10 November 2008
US court fines three drug firms $7.3M for overcharging Medicaid
10 November 2008
FDA delays NDA reviews despite budget rise
3 November 2008
S-P profit falls 21%, still up on predictions
27 October 2008
Humira shows three year fistula effect
27 October 2008
Schering-Plough to cut 1,000 sales jobs
29 September 2008
Caelyx plus first-line chemo prolongs PFS in MBC
22 September 2008
Schering-Plough closes sale of animal health products to Pfizer
22 September 2008
China hep C market to grow to $150M in 2012
15 September 2008
Divided opinion on Vytorin despite
8 September 2008
China's hep B market $800M by 2012
8 September 2008
FDA investigates Vytorin link to cancer risk in SEAS study
1 September 2008
UK NICE's recommendation on J&J's and S-P's Remicade analyzed
1 September 2008
S-P expands in China; buys out JV partners
18 August 2008
Stock Commentary - New York week to Aug 4, 2008
11 August 2008
S-P's acadesine mimics exercise benefits in mice
11 August 2008
S-P's boceprevir shows 74% SVR in HCV
11 August 2008
Stock Commentary - New York week to July 21, 2008
28 July 2008
EU's pediatric drug c'tee celebrates first birthday
28 July 2008
S-P profit down again on Organon charges
28 July 2008
S-P gains approval for hayfever drug in Japan
28 July 2008
Stock Commentary - New York week to July 14, 2008
21 July 2008
Mixed results for S-P's Pegintron in melanoma
21 July 2008
S-P fertility treatment achieves equivalence
14 July 2008
Black box warnings on fluoroquinolone
14 July 2008
UPDATE: FDA panel votes in favor of outcomes over surrogate markers in diabetes drug approval
7 July 2008
Singapore reinforces position as a global site for pharma and biotech; output quadruples
30 June 2008
Stock Commentary - New York week to June 16, 2008
23 June 2008
Phytopharm's Phytopica launched in Hong Kong
16 June 2008
S-P's Aerius reduces allergy symptoms
16 June 2008
Stock Commentary - New York week to June 2, 2008
9 June 2008
S-P's Bridion gets nod from EMEA's CHMP
9 June 2008
Changes in Shanghai Schering-Plough
9 June 2008
S-P to initiate Ph III boceprevir program
2 June 2008
Stock Commentary - Europe - week to May 19, 2008
26 May 2008
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
